Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPHNIS: Dapagliflozin for Lipids and Glycemic Control in T2DM
NCT02577159Phase 4Unknown
- Sponsor
- The University of Osaka
- Start
- Jul 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by The University of Osaka. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02577159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02577159.